公开(公告)号：US20210230296A1

公开(公告)日：2021-07-29

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200277397A1

公开(公告)日：2020-09-03

申请号：US16813167

申请日：2020-03-09

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  C12N15/79 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20160333095A1

公开(公告)日：2016-11-17

申请号：US15110414

申请日：2015-01-08

Applicant: GENMAB A/S

Inventor： Edward Norbert VAN DEN BRINK ,  Joost J. NEIJSSEN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Isil ALTINTAS ,  Paul PARREN ,  Rik RADEMAKER

IPC: C07K16/28 ,  C07K16/42 ,  C07K16/32 ,  G01N33/68

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4241 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6872 ,  G01N2333/7051

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Abstract translation: 本发明涉及结合CD3的人源化或嵌合抗体。 此外，它还涉及双特异性抗体，组合物，药物组合物，所述抗体在治疗疾病中的用途，以及治疗方法。

公开(公告)号：US20220389101A1

公开(公告)日：2022-12-08

申请号：US17739940

申请日：2022-05-09

Applicant: GENMAB A/S

Inventor： Rik RADEMAKER ,  Isil ALTINTAS ,  Patrick ENGELBERTS ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/32

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20210070877A1

公开(公告)日：2021-03-11

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200239579A1

公开(公告)日：2020-07-30

申请号：US16491464

申请日：2018-03-09

Applicant: GENMAB A/S

Inventor： Isil ALTINTAS ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rik RADEMAKER ,  Paul PARREN ,  Bart DE GOEIJ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.